Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02754726 · ClinicalTrials.gov registry record · Phase 2
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 2 study, sponsored by HonorHealth Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT02754726 is a Phase 2 study that has completed, run by HonorHealth Research Institute. The registered enrollment target is 35 participants.
The verdict
NCT02754726, a Phase 2 study, has completed, sponsored by HonorHealth Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if the study drugs nivolumab, albumin- bound paclitaxel, paricalcitol, cisplatin, and gemcitabine given together are safe and effective when combined to treat advanced pancreatic cancer.
Interventions
- DRUG Cisplatin
- DRUG Nivolumab
- DRUG Gemcitabine
- DRUG Paricalcitol
- DRUG Albumin-bound paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2016-04 |
| Est. Completion | 2024-03-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02754726
The ClinicalTrials.gov registry entry for NCT02754726 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HonorHealth Research Institute, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT02754726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02754726 about?
NCT02754726 is a clinical study titled "Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma". The purpose of this study is to find out if the study drugs nivolumab, albumin- bound paclitaxel, paricalcitol, cisplatin, and gemcitabine given together are safe and effective when combined to treat advanced pancreatic cancer.
What is the current status of trial NCT02754726?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2016-04. Estimated completion is 2024-03-22.
What interventions are being tested in trial NCT02754726?
The interventions under investigation include: Cisplatin (DRUG), Nivolumab (DRUG), Gemcitabine (DRUG), Paricalcitol (DRUG), Albumin-bound paclitaxel (DRUG).
Who is sponsoring clinical trial NCT02754726?
This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.